Industrial Logistics Properties Trust (ILPT) came out with quarterly funds from operations (FFO) of $0.49 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to FFO of $0.46 per share a year ago. These figures are adjusted for non-recurring items.

– Zacks

This quarterly report represents an FFO surprise of 4.26%. A quarter ago, it was expected that this company would post FFO of $0.48 per share when it actually produced FFO of $0.46, delivering a surprise of -4.17%.

Over the last four quarters, the company has surpassed consensus FFO estimates two times.

Industrial Logistics Properties Trust, which belongs to the Zacks REIT and Equity Trust – Other industry, posted revenues of $56.5 million for the quarter ended December 2021, missing the Zacks Consensus Estimate by 0.19%. This compares to year-ago revenues of $60.08 million. The company has topped consensus revenue estimates just once over the last four quarters.

The sustainability of the stock’s immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management’s commentary on the earnings call.

Industrial Logistics Properties Trust shares have lost about 13.6% since the beginning of the year versus the S&P 500’s decline of -7.7%.

What’s Next for Industrial Logistics Properties Trust?

While Industrial Logistics Properties Trust has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company’s FFO outlook. Not only does this include current consensus FFO expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Industrial Logistics Properties Trust: mixed. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus FFO estimate is $0.50 on $57.65 million in revenues for the coming quarter and $1.99 on $235.09 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, REIT and Equity Trust – Other is currently in the bottom 30% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, RLJ Lodging (RLJ), has yet to report results for the quarter ended December 2021. The results are expected to be released on February 23.

This hotel real estate investment trust is expected to post quarterly earnings of $0.19 per share in its upcoming report, which represents a year-over-year change of +167.9%. The consensus EPS estimate for the quarter has been revised 5.8% lower over the last 30 days to the current level.

RLJ Lodging’s revenues are expected to be $247.44 million, up 171.7% from the year-ago quarter.

Zacks Names “Single Best Pick to Double”

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Industrial Logistics Properties Trust (ILPT): Free Stock Analysis Report
 
RLJ Lodging Trust (RLJ): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

InMed Pharmaceuticals Inc. (INM) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.37 per share a year ago. These figures are adjusted for non-recurring items.

– Zacks

This quarterly report represents an earnings surprise of -29.17%. A quarter ago, it was expected that this company would post a loss of $0.35 per share when it actually produced a loss of $0.25, delivering a surprise of 28.57%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

InMed Pharmaceuticals Inc., which belongs to the Zacks Medical – Drugs industry, posted revenues of $0.27 million for the quarter ended December 2021, surpassing the Zacks Consensus Estimate by 6%. This compares to zero revenues a year ago.

The sustainability of the stock’s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management’s commentary on the earnings call.

InMed Pharmaceuticals Inc. Shares have lost about 9.9% since the beginning of the year versus the S&P 500’s decline of -7.3%.

What’s Next for InMed Pharmaceuticals Inc.

While InMed Pharmaceuticals Inc. Has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company’s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for InMed Pharmaceuticals Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.22 on $0.43 million in revenues for the coming quarter and -$0.93 on $1.2 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical – Drugs is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Pacira (PCRX), another stock in the same industry, has yet to report results for the quarter ended December 2021.

This specialty drugmaker is expected to post quarterly earnings of $0.83 per share in its upcoming report, which represents a year-over-year change of -4.6%. The consensus EPS estimate for the quarter has been revised 3% lower over the last 30 days to the current level.

Pacira’s revenues are expected to be $158.17 million, up 20.8% from the year-ago quarter.

Just Released: Zacks Top 10 Stocks for 2022

In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?

Last year’s 2021 Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys

Access Zacks Top 10 Stocks for 2022 today >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
InMed Pharmaceuticals Inc. (INM): Free Stock Analysis Report
 
Pacira BioSciences, Inc. (PCRX): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Ziff Davis (ZD) came out with quarterly earnings of $2.17 per share, beating the Zacks Consensus Estimate of $2.08 per share. This compares to earnings of $3.11 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 4.33%. A quarter ago, it was expected that this internet and cloud services company would post earnings of $2.21 per share when it actually produced earnings of $2.34, delivering a surprise of 5.88%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Ziff Davis, which belongs to the Zacks Internet – Software industry, posted revenues of $408.63 million for the quarter ended December 2021, surpassing the Zacks Consensus Estimate by 0.88%. This compares to year-ago revenues of $469.24 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock’s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management’s commentary on the earnings call.

Ziff Davis shares have lost about 7.7% since the beginning of the year versus the S&P 500’s decline of -7.3%.

What’s Next for Ziff Davis?

While Ziff Davis has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company’s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Ziff Davis: mixed. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.62 on $330.5 million in revenues for the coming quarter and $7.36 on $1.52 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet – Software is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

PubMatic, Inc. (PUBM), another stock in the same industry, has yet to report results for the quarter ended December 2021. The results are expected to be released on February 28.

This company is expected to post quarterly earnings of $0.27 per share in its upcoming report, which represents a year-over-year change of -20.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

PubMatic, Inc.’s revenues are expected to be $75.34 million, up 34% from the year-ago quarter.

Just Released: Zacks Top 10 Stocks for 2022

In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?

Last year’s 2021 Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys

Access Zacks Top 10 Stocks for 2022 today >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Ziff Davis, Inc. (ZD): Free Stock Analysis Report
 
PubMatic, Inc. (PUBM): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Palatin Technologies, Inc. (PTN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items.

– Zacks

This quarterly report represents an earnings surprise of -33.33%. A quarter ago, it was expected that this company would post a loss of $0.03 per share when it actually produced a loss of $0.03, delivering no surprise.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

Palatin Technologies, Inc., which belongs to the Zacks Medical – Biomedical and Genetics industry, posted revenues of $0.32 million for the quarter ended December 2021, surpassing the Zacks Consensus Estimate by 78.89%. This compares to year-ago revenues of $-0.16 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock’s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management’s commentary on the earnings call.

Palatin Technologies, Inc. Shares have lost about 21.6% since the beginning of the year versus the S&P 500’s decline of -7.3%.

What’s Next for Palatin Technologies, Inc.

While Palatin Technologies, Inc. Has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company’s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Palatin Technologies, Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.04 on $0.2 million in revenues for the coming quarter and -$0.13 on $4.6 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical – Biomedical and Genetics is currently in the bottom 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Cytokinetics (CYTK), has yet to report results for the quarter ended December 2021. The results are expected to be released on February 24.

This biopharmaceutical company is expected to post quarterly loss of $0.89 per share in its upcoming report, which represents a year-over-year change of -43.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Cytokinetics’ revenues are expected to be $4.84 million, down 28% from the year-ago quarter.

Just Released: Zacks Top 10 Stocks for 2022

In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?

Last year’s 2021 Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys

Access Zacks Top 10 Stocks for 2022 today >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Palatin Technologies, Inc. (PTN): Free Stock Analysis Report
 
Cytokinetics, Incorporated (CYTK): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

In the latest trading session, StoneCo Ltd. (STNE) closed at $12.45, marking a -1.81% move from the previous day. This change lagged the S&P 500’s 0.38% loss on the day. Meanwhile, the Dow lost 0.5%, and the Nasdaq, a tech-heavy index, lost 0.05%.

– Zacks

Coming into today, shares of the company had lost 23.71% in the past month. In that same time, the Computer and Technology sector lost 8.71%, while the S&P 500 lost 6.25%.

StoneCo Ltd. will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.01, down 94.74% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $200.72 million, up 8.12% from the prior-year quarter.

Investors might also notice recent changes to analyst estimates for StoneCo Ltd.These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company’s business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 4.72% lower. StoneCo Ltd. is holding a Zacks Rank of #5 (Strong Sell) right now.

In terms of valuation, StoneCo Ltd. is currently trading at a Forward P/E ratio of 37.66. This represents a discount compared to its industry’s average Forward P/E of 52.41.

The Internet – Software industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 158, which puts it in the bottom 39% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow STNE in the coming trading sessions, be sure to utilize Zacks.com.

Just Released: Zacks Top 10 Stocks for 2022

In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?

Last year’s 2021 Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys

Access Zacks Top 10 Stocks for 2022 today >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
StoneCo Ltd. (STNE): Free Stock Analysis Report
 
To read this article on Zacks.com click here.

BridgeBio Pharma (BBIO) closed at $8.54 in the latest trading session, marking a -1.61% move from the prior day. This change lagged the S&P 500’s 0.38% loss on the day. Meanwhile, the Dow lost 0.5%, and the Nasdaq, a tech-heavy index, lost 0.05%.

– Zacks

Prior to today’s trading, shares of the rare disease drug developer had lost 31.92% over the past month. This has lagged the Medical sector’s loss of 5.24% and the S&P 500’s loss of 6.25% in that time.

Investors will be hoping for strength from BridgeBio Pharma as it approaches its next earnings release. The company is expected to report EPS of -$0.83, up 17.82% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $33.19 million, up 27561.67% from the year-ago period.

It is also important to note the recent changes to analyst estimates for BridgeBio Pharma. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company’s business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.69% higher. BridgeBio Pharma currently has a Zacks Rank of #3 (Hold).

The Medical – Generic Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 216, putting it in the bottom 16% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Just Released: Zacks Top 10 Stocks for 2022

In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?

Last year’s 2021 Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys

Access Zacks Top 10 Stocks for 2022 today >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
BridgeBio Pharma, Inc. (BBIO): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Materialise (MTLS) closed the most recent trading day at $20.35, moving -0.25% from the previous trading session. This change was narrower than the S&P 500’s 0.38% loss on the day. At the same time, the Dow lost 0.5%, and the tech-heavy Nasdaq lost 0.05%.

– Zacks

Prior to today’s trading, shares of the 3D printing software and medical and industrial products company had lost 1.45% over the past month. This has was narrower than the Computer and Technology sector’s loss of 8.71% and the S&P 500’s loss of 6.25% in that time.

Wall Street will be looking for positivity from Materialise as it approaches its next earnings report date. The company is expected to report EPS of $0.06, up 50% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $60.92 million, up 9.58% from the year-ago period.

Investors should also note any recent changes to analyst estimates for Materialise. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company’s business and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Materialise is currently sporting a Zacks Rank of #3 (Hold).

Investors should also note Materialise’s current valuation metrics, including its Forward P/E ratio of 87.43. This valuation marks a premium compared to its industry’s average Forward P/E of 52.41.

The Internet – Software industry is part of the Computer and Technology sector. This group has a Zacks Industry Rank of 158, putting it in the bottom 39% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

Just Released: Zacks Top 10 Stocks for 2022

In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?

Last year’s 2021 Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys

Access Zacks Top 10 Stocks for 2022 today >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Materialise NV (MTLS): Free Stock Analysis Report
 
To read this article on Zacks.com click here.

ContextLogic Inc. (WISH) closed at $2.24 in the latest trading session, marking a -0.88% move from the prior day. This move lagged the S&P 500’s daily loss of 0.38%. At the same time, the Dow lost 0.5%, and the tech-heavy Nasdaq lost 0.05%.

– Zacks

Coming into today, shares of the company had lost 10.67% in the past month. In that same time, the Retail-Wholesale sector lost 6.47%, while the S&P 500 lost 6.25%.

Wall Street will be looking for positivity from ContextLogic Inc. as it approaches its next earnings report date. In that report, analysts expect ContextLogic Inc. to post earnings of -$0.10 per share. This would mark year-over-year growth of 96.71%. Meanwhile, our latest consensus estimate is calling for revenue of $303.63 million, down 61.76% from the prior-year quarter.

Investors might also notice recent changes to analyst estimates for ContextLogic Inc.These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company’s business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. ContextLogic Inc. is holding a Zacks Rank of #4 (Sell) right now.

The Internet – Commerce industry is part of the Retail-Wholesale sector. This industry currently has a Zacks Industry Rank of 227, which puts it in the bottom 11% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

Just Released: Zacks Top 10 Stocks for 2022

In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?

Last year’s 2021 Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys

Access Zacks Top 10 Stocks for 2022 today >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ContextLogic Inc. (WISH): Free Stock Analysis Report
 
To read this article on Zacks.com click here.

Chesapeake Energy (CHK) closed at $67.77 in the latest trading session, marking a -2% move from the prior day. This move lagged the S&P 500’s daily loss of 0.38%. At the same time, the Dow lost 0.5%, and the tech-heavy Nasdaq lost 0.05%.

– Zacks

Coming into today, shares of the oil and gas company had lost 3.31% in the past month. In that same time, the Oils-Energy sector gained 8.31%, while the S&P 500 lost 6.25%.

Wall Street will be looking for positivity from Chesapeake Energy as it approaches its next earnings report date. This is expected to be February 23, 2022. In that report, analysts expect Chesapeake Energy to post earnings of $2.43 per share. This would mark year-over-year growth of 105.71%. Meanwhile, our latest consensus estimate is calling for revenue of $1.07 billion, down 15.02% from the prior-year quarter.

Investors might also notice recent changes to analyst estimates for Chesapeake Energy. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company’s business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 16.76% higher. Chesapeake Energy is holding a Zacks Rank of #3 (Hold) right now.

Looking at its valuation, Chesapeake Energy is holding a Forward P/E ratio of 6.59. This represents a discount compared to its industry’s average Forward P/E of 18.52.

The Alternative Energy – Other industry is part of the Oils-Energy sector. This group has a Zacks Industry Rank of 165, putting it in the bottom 36% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Just Released: Zacks Top 10 Stocks for 2022

In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?

Last year’s 2021 Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys

Access Zacks Top 10 Stocks for 2022 today >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Chesapeake Energy Corporation (CHK): Free Stock Analysis Report
 
To read this article on Zacks.com click here.

Li Auto Inc. Sponsored ADR (LI) closed at $28.48 in the latest trading session, marking a +1.21% move from the prior day. This move outpaced the S&P 500’s daily loss of 0.38%. Meanwhile, the Dow lost 0.5%, and the Nasdaq, a tech-heavy index, lost 0.05%.

– Zacks

Prior to today’s trading, shares of the company had lost 9.6% over the past month. This has was narrower than the Auto-Tires-Trucks sector’s loss of 16.39% and lagged the S&P 500’s loss of 6.25% in that time.

Li Auto Inc. Sponsored ADR will be looking to display strength as it nears its next earnings release.

Investors might also notice recent changes to analyst estimates for Li Auto Inc. Sponsored ADR. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company’s business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Li Auto Inc. Sponsored ADR is currently sporting a Zacks Rank of #4 (Sell).

The Automotive – Foreign industry is part of the Auto-Tires-Trucks sector. This group has a Zacks Industry Rank of 204, putting it in the bottom 20% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow LI in the coming trading sessions, be sure to utilize Zacks.com.

Just Released: Zacks Top 10 Stocks for 2022

In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?

Last year’s 2021 Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys

Access Zacks Top 10 Stocks for 2022 today >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Li Auto Inc. Sponsored ADR (LI): Free Stock Analysis Report
 
To read this article on Zacks.com click here.